Use of pyridoxine-alpha-ketoglutarate (PAK) in hepatic encephalopathy

G. R. Corazza, C. Tacconi, G. Zoli

Research output: Contribution to journalArticlepeer-review


Pyridoxine-alpha-ketoglutarate (PAK) was administered to patients with high blood ammonia levels and with clinical signs of hepatic encephalopathy (HE). Plasma concentrations of ammonia decreased and clinical symptomatology improved. The activity of PAK was greater than that of lactulose in lowering blood ammonia levels but not significantly different in its relief of neuropsychic symptoms.

Original languageEnglish
Pages (from-to)7-13
Number of pages7
JournalInternational Journal of Clinical Pharmacology Research
Issue number4 Suppl. 1
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Use of pyridoxine-alpha-ketoglutarate (PAK) in hepatic encephalopathy'. Together they form a unique fingerprint.

Cite this